Literature DB >> 24922631

MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy.

Angelika Bezan1, Armin Gerger1, Martin Pichler2.   

Abstract

Testicular germ cell tumors (TGCTs) represent the most common type of solid tumors among men aged 15 to 40 years. An increasing incidence has been recorded in developed countries. In clinical practice, TGCTs are classified as seminomas and non-seminomatous tumors. Non-seminomatous tumors often contain multiple different cell types and can be further sub-divided according to the histological and cellular phenotype in embryonal carcinomas, choriocarcinomas, yolk sac tumors and teratomas. For the clinical management of TGCTs, blood-based markers such as lactate dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin are essential tools for diagnosis, risk assessment and patient's prognosis. However, only 60% of patients with TGCTs show increased serum levels of these tumor markers. This proportion of patients is even lower for those with seminomas or pure embryonal carcinomas as alpha-fetoprotein is predominantly related to yolk sac tumor and human chorionic gonadotropin to choriocarcinoma. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Testicular cancer; diagnosis; microRNAs; pathophysiology; prognosis; review

Mesh:

Substances:

Year:  2014        PMID: 24922631

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

Review 1.  Testicular germ cell tumor genomics.

Authors:  Solomon L Woldu; James F Amatruda; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2017-01       Impact factor: 2.309

Review 2.  Genetics of testicular germ cell tumors.

Authors:  Nirmish Singla; John T Lafin; Rashed A Ghandour; Samuel Kaffenberger; James F Amatruda; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2019-07       Impact factor: 2.309

3.  Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.

Authors:  Petra Anheuser; Arlo Radtke; Christian Wülfing; Jennifer Kranz; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2017-06-07       Impact factor: 2.089

Review 4.  Will Testicular Germ Cell Tumors Remain Untargetable?

Authors:  Fouad Aoun; Hampig Raphael Kourie; Simone Albisinni; Thierry Roumeguère
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

5.  The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.

Authors:  Arlo Radtke; Finja Hennig; Raphael Ikogho; Johannes Hammel; Petra Anheuser; Christian Wülfing; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2018-04-26       Impact factor: 2.089

6.  Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma.

Authors:  Gazanfer Belge; Francesca Grobelny; Cord Matthies; Arlo Radtke; Klaus-Peter Dieckmann
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 7.  Male reproductive cancers and infertility: a mutual relationship.

Authors:  Eva Tvrda; Ashok Agarwal; Nawaf Alkuhaimi
Journal:  Int J Mol Sci       Date:  2015-03-31       Impact factor: 5.923

Review 8.  The role of microRNAs expression in laryngeal cancer.

Authors:  Xin Yu; Zheng Li
Journal:  Oncotarget       Date:  2015-09-15

Review 9.  Current Status of Long Non-Coding RNAs in Human Breast Cancer.

Authors:  Stefanie Cerk; Daniela Schwarzenbacher; Jan Basri Adiprasito; Michael Stotz; Georg C Hutterer; Armin Gerger; Hui Ling; George Adrian Calin; Martin Pichler
Journal:  Int J Mol Sci       Date:  2016-09-06       Impact factor: 5.923

10.  Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs.

Authors:  T B Rounge; K Furu; R I Skotheim; T B Haugen; T Grotmol; E Enerly
Journal:  Mol Cancer       Date:  2015-08-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.